Novartis: Adenocarcinoma trials
The registry lists 14 Adenocarcinoma studies with Novartis as lead sponsor. 2 are open to participants now and 5 have results posted.
Phase 1 5Phase 2 8Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsRecruitingNCT07801508Phase 1
- A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung CancersRecruitingNCT07117214Phase 1
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the PancreasCompletedNCT01433263Phase 2Results posted
- Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedNCT00719264Phase 2Results posted
- RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCompletedNCT00688753Phase 2Results posted
- Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate CancerCompletedNCT00667862Phase 2Results posted
- Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive GlioblastomaCompletedNCT00154375Phase 3Results posted
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
- Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung CancerCompletedNCT01577654Phase 2
- Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer PatientsCompletedNCT01487785Phase 1
- Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)CompletedNCT01002924Phase 2
- Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)CompletedNCT00511485Phase 2
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2